{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:48:08Z","timestamp":1794307688773,"version":"4.9.0"},"reference-count":361,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012737","name":"Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There are many pharmacologic therapies that are being used or considered for treatment of coronavirus disease 2019 (COVID-19), with rapidly changing efficacy and safety evidence from trials. The objective was to develop evidence-based, rapid, living guidelines intended to support patients, clinicians, and other healthcare professionals in their decisions about treatment and management of patients with COVID-19. In March 2020, the Infectious Diseases Society of America (IDSA) formed a multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise to regularly review the evidence and make recommendations about the treatment and management of persons with COVID-19. The process used a living guideline approach and followed a rapid recommendation development checklist. The panel prioritized questions and outcomes. A systematic review of the peer-reviewed and grey literature was conducted at regular intervals. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to assess the certainty of evidence and make recommendations. Based on the most recent search conducted on 31 May 2022, the IDSA guideline panel has made 32 recommendations for the treatment and management of the following groups\/populations: pre- and postexposure prophylaxis, ambulatory with mild-to-moderate disease, and hospitalized with mild-to-moderate, severe but not critical, and critical disease. As these are living guidelines, the most recent recommendations can be found online at: https:\/\/idsociety.org\/COVID19guidelines. At the inception of its work, the panel has expressed the overarching goal that patients be recruited into ongoing trials. Since then, many trials were conducted that provided much-needed evidence for COVID-19 therapies. There still remain many unanswered questions as the pandemic evolved, which we hope future trials can answer.<\/jats:p>","DOI":"10.1093\/cid\/ciac724","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T16:39:43Z","timestamp":1662050383000},"page":"e250-e349","source":"Crossref","is-referenced-by-count":196,"title":["Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)"],"prefix":"10.1093","volume":"78","author":[{"given":"Adarsh","family":"Bhimraj","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Houston Methodist Hospital , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University , Hamilton, Ontario , Canada"},{"name":"Department of Medicine, Case Western Reserve University, School of Medicine , Cleveland, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Hirsch","family":"Shumaker","sequence":"additional","affiliation":[{"name":"Department of Medicine, Case Western Reserve University, School of Medicine , Cleveland, Ohio , USA"},{"name":"VA Northeast Ohio Healthcare System , Cleveland, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R","family":"Baden","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Chi-Chung","family":"Cheng","sequence":"additional","affiliation":[{"name":"Queen Mary Hospital, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong , Hong Kong Special Administrative Region , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M","family":"Edwards","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center , Nashville, Tennessee , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason C","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Temple University , Philadelphia, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh T","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Muller","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University , Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari M","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Antimicrobial Stewardship Program and Division of Infectious Diseases, Boston Children's Hospital and Department of Pediatrics, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C","family":"O\u2019Horo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Joint Appointment Pulmonary and Critical Care Medicine, Mayo Clinic , Rochester, Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W","family":"Shafer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University , Palo Alto, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shmuel","family":"Shoham","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Hassan","family":"Murad","sequence":"additional","affiliation":[{"name":"Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic , Rochester, Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem A","family":"Mustafa","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, University of Kansas Medical Center , Kansas City, Kansas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Sultan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis VA Healthcare System , Minneapolis, Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yngve","family":"Falck-Ytter","sequence":"additional","affiliation":[{"name":"Department of Medicine, Case Western Reserve University, School of Medicine , Cleveland, Ohio , USA"},{"name":"VA Northeast Ohio Healthcare System , Cleveland, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"2024062715541743000_ciac724-B1","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"2024062715541743000_ciac724-B2","volume-title":"Coronavirus disease 2019 (COVID-19) situation report\u201475","author":"World Health Organization","year":"2020"},{"key":"2024062715541743000_ciac724-B3","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"2024062715541743000_ciac724-B4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12961-018-0330-0","article-title":"Development of rapid guidelines: 3. GIN-McMaster Guideline Development Checklist extension for rapid recommendations","volume":"16","author":"Morgan","year":"2018","journal-title":"Health Res Policy Syst"},{"issue":"4","key":"2024062715541743000_ciac724-B5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2024062715541743000_ciac724-B6","author":"US Food and Drug Administration"},{"key":"2024062715541743000_ciac724-B7","volume-title":"Scoping. Interim process and methods for developing rapid guidelines on COVID-19 (PMG35)","author":"National Institute for Health and Care Excellence","year":"2020"},{"issue":"5","key":"2024062715541743000_ciac724-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v049.i05","article-title":"Closing the gap between methodologists and end-users: R as a computational back-end","volume":"49","author":"Wallace","year":"2012","journal-title":"J Stat Softw"},{"key":"2024062715541743000_ciac724-B9","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019","edition":"2nd ed"},{"key":"2024062715541743000_ciac724-B10","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"2024062715541743000_ciac724-B11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2024062715541743000_ciac724-B12","author":"GRADEpro GDT"},{"issue":"2","key":"2024062715541743000_ciac724-B13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12016-010-8243-x","article-title":"Hydroxychloroquine: from malaria to autoimmunity","volume":"42","author":"Ben-Zvi","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"2024062715541743000_ciac724-B14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbrc.2004.08.085","article-title":"In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine","volume":"323","author":"Keyaerts","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"2024062715541743000_ciac724-B15","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection","volume":"58","author":"Dyall","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2024062715541743000_ciac724-B16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"2024062715541743000_ciac724-B17","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024062715541743000_ciac724-B18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol J"},{"issue":"1","key":"2024062715541743000_ciac724-B19","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2024062715541743000_ciac724-B20","doi-asserted-by":"publisher","first-page":"e00394-19","DOI":"10.1128\/AAC.00394-19","article-title":"Azithromycin protects against Zika virus infection by upregulating virus-induced type I and III interferon responses","volume":"63","author":"Li","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2024062715541743000_ciac724-B21","first-page":"e84","article-title":"Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs","volume":"3","author":"Kouznetsova","year":"2014","journal-title":"Emerg Microbes Infect"},{"issue":"3","key":"2024062715541743000_ciac724-B22","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1183\/09031936.00095809","article-title":"Azithromycin induces anti-viral responses in bronchial epithelial cells","volume":"36","author":"Gielen","year":"2010","journal-title":"Eur Respir J"},{"issue":"1","key":"2024062715541743000_ciac724-B23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1006\/excr.2002.5613","article-title":"Azithromycin, a lysosomotropic antibiotic, has distinct effects on fluid-phase and receptor-mediated endocytosis, but does not impair phagocytosis in J774 macrophages","volume":"281","author":"Tyteca","year":"2002","journal-title":"Exp Cell Res"},{"key":"2024062715541743000_ciac724-B24","doi-asserted-by":"crossref","first-page":"28698","DOI":"10.1038\/srep28698","article-title":"Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients","volume":"6","author":"Menzel","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"2024062715541743000_ciac724-B25","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1006\/bbrc.1995.1727","article-title":"Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells: a potential mechanism of its anti-inflammatory action","volume":"210","author":"Takizawa","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"2024062715541743000_ciac724-B26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jac\/dkh309","article-title":"Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis","volume":"54","author":"Schultz","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2024062715541743000_ciac724-B27","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ijid.2020.06.099","article-title":"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19","volume":"97","author":"Arshad","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2024062715541743000_ciac724-B28","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMoa2019014","article-title":"Hydroxychloroquine with or without azithromycin in mild-to-moderate COVID-19","volume":"383","author":"Cavalcanti","year":"2020","journal-title":"N Engl J Med"},{"key":"2024062715541743000_ciac724-B29","article-title":"Effect of hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multi-centre, randomized, controlled trial","author":"Horby","year":"2020","journal-title":"medRxiv"},{"issue":"2","key":"2024062715541743000_ciac724-B30","first-page":"215","article-title":"A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19","volume":"49","author":"Chen","year":"2020","journal-title":"J Zhejiang Univ (Med Sci)"},{"key":"2024062715541743000_ciac724-B31","article-title":"Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial","author":"Chen","year":"2020","journal-title":"medRxiv,"},{"issue":"6","key":"2024062715541743000_ciac724-B32","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for COVID-19\u2014interim WHO solidarity trial results","volume":"384","author":"WHO Solidarity Trial Consortium","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"2024062715541743000_ciac724-B33","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1001\/jama.2020.22240","article-title":"Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial","volume":"324","author":"Self","year":"2020","journal-title":"JAMA"},{"issue":"10","key":"2024062715541743000_ciac724-B34","doi-asserted-by":"crossref","first-page":"ofaa446","DOI":"10.1093\/ofid\/ofaa446","article-title":"Treating COVID-19 with hydroxychloroquine (TEACH): a multicenter, double-blind randomized controlled trial in hospitalized patients","volume":"7","author":"Ulrich","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2024062715541743000_ciac724-B35","doi-asserted-by":"crossref","first-page":"m1849","DOI":"10.1136\/bmj.m1849","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","volume":"369","author":"Tang","year":"2020","journal-title":"BMJ"},{"issue":"25","key":"2024062715541743000_ciac724-B36","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with COVID-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N Engl J Med"},{"key":"2024062715541743000_ciac724-B37","article-title":"Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19","author":"Magagnoli","year":"2020","journal-title":"medRxiv,"},{"key":"2024062715541743000_ciac724-B38","article-title":"No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial","author":"Mahevas","year":"2020","journal-title":"medRxiv,"},{"issue":"24","key":"2024062715541743000_ciac724-B39","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1001\/jama.2020.8630","article-title":"Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state","volume":"323","author":"Rosenberg","year":"2020","journal-title":"JAMA"},{"issue":"10","key":"2024062715541743000_ciac724-B40","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s11427-020-1732-2","article-title":"Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19","volume":"63","author":"Yu","year":"2020","journal-title":"Sci China Life Sci"},{"key":"2024062715541743000_ciac724-B41","article-title":"Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-an observational study","author":"Ip","year":"2020","journal-title":"medRxiv,"},{"key":"2024062715541743000_ciac724-B42","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ijcard.2020.05.036","article-title":"Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin","volume":"316","author":"Cipriani","year":"2020","journal-title":"Int J Cardiol"},{"issue":"4","key":"2024062715541743000_ciac724-B43","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.medmal.2020.03.006","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection","volume":"50","author":"Molina","year":"2020","journal-title":"M\u00e9d Mal Infect"},{"key":"2024062715541743000_ciac724-B44","doi-asserted-by":"crossref","first-page":"101663","DOI":"10.1016\/j.tmaid.2020.101663","article-title":"Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study","volume":"34","author":"Gautret","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"2024062715541743000_ciac724-B45","article-title":"The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine\/azithromycin","author":"Chorin","year":"2020,","journal-title":"medRxiv,"},{"issue":"4","key":"2024062715541743000_ciac724-B46","first-page":"808","article-title":"Discontinuation of antimalarial drugs in systemic lupus erythematosus","volume":"26","author":"Wang","year":"1999","journal-title":"J Rheumatol"},{"issue":"9","key":"2024062715541743000_ciac724-B47","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2165\/11536520-000000000-00000","article-title":"Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review","volume":"33","author":"Youngster","year":"2010","journal-title":"Drug Saf"},{"issue":"3","key":"2024062715541743000_ciac724-B48","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/acr.23296","article-title":"Examination of hydroxychloroquine use and hemolytic anemia in G6PDH-deficient patients","volume":"70","author":"Mohammad","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024062715541743000_ciac724-B49","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/ejh.13432","article-title":"COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency","volume":"105","author":"Beauverd","year":"2020","journal-title":"Eur J Haematol"},{"key":"2024062715541743000_ciac724-B50","doi-asserted-by":"publisher","first-page":"E194","DOI":"10.1002\/ajh.25862","article-title":"G6PD deficiency-associated hemolysis and methemoglobinemia in a COVID-19 patient treated with chloroquine","volume":"95","author":"Kuipers","year":"2020","journal-title":"Am J Hematol"},{"key":"2024062715541743000_ciac724-B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/23744235.2020.1774644","article-title":"A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine","author":"Maillart","year":"2020","journal-title":"Infect Dis (Lond)"},{"issue":"5","key":"2024062715541743000_ciac724-B52","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","article-title":"Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases","volume":"23","author":"Rainsford","year":"2015","journal-title":"Inflammopharmacology"},{"issue":"5","key":"2024062715541743000_ciac724-B53","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/RHU.0b013e31829d5e50","article-title":"Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus","volume":"19","author":"Morgan","year":"2013","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"2024062715541743000_ciac724-B54","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/15563650500514558","article-title":"Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia","volume":"44","author":"Chen","year":"2006","journal-title":"Clin Toxicol (Phila)"},{"key":"2024062715541743000_ciac724-B55","article-title":"Syncope in a patient being treated for hepatic and intestinal amoebiasis","volume":"2012","author":"Yelve","year":"2012","journal-title":"BMJ Case Rep"},{"issue":"2","key":"2024062715541743000_ciac724-B56","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/j.ijcard.2007.04.055","article-title":"Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine","volume":"127","author":"Stas","year":"2008","journal-title":"Int J Cardiol"},{"issue":"20","key":"2024062715541743000_ciac724-B57","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"2024062715541743000_ciac724-B58","first-page":"105","article-title":"Macrolide antibacterials. Drug interactions of clinical significance","volume":"13","author":"von Rosensteil","year":"1995","journal-title":"Drug Saf"},{"issue":"3","key":"2024062715541743000_ciac724-B59","doi-asserted-by":"crossref","first-page":"344","DOI":"10.7326\/M20-6519","article-title":"Hydroxychloroquine as postexposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 infection: a randomized trial","volume":"174","author":"Barnabas","year":"2021","journal-title":"Ann Intern Med"},{"issue":"6","key":"2024062715541743000_ciac724-B60","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa2016638","article-title":"A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19","volume":"383","author":"Boulware","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"2024062715541743000_ciac724-B61","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa2021801","article-title":"A cluster-randomized trial of hydroxychloroquine for prevention of COVID-19","volume":"384","author":"Mitja","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2024062715541743000_ciac724-B62","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcv.2004.03.003","article-title":"In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds","volume":"31","author":"Chen","year":"2004","journal-title":"J Clin Virol"},{"issue":"27","key":"2024062715541743000_ciac724-B63","doi-asserted-by":"crossref","first-page":"10012","DOI":"10.1073\/pnas.0403596101","article-title":"Small molecules targeting severe acute respiratory syndrome human coronavirus","volume":"101","author":"Wu","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"2024062715541743000_ciac724-B64","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with lopinavir\/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J Infect Dis"},{"issue":"3","key":"2024062715541743000_ciac724-B65","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"issue":"6","key":"2024062715541743000_ciac724-B66","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ijantimicag.2014.07.026","article-title":"Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen","volume":"44","author":"Spanakis","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"2024062715541743000_ciac724-B67","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3851\/IMP3002","article-title":"Combination therapy with lopinavir\/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome","volume":"21","author":"Kim","year":"2016","journal-title":"Antivir Ther"},{"issue":"10238","key":"2024062715541743000_ciac724-B68","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"2024062715541743000_ciac724-B69","doi-asserted-by":"crossref","first-page":"101188","DOI":"10.1016\/j.eclinm.2021.101188","article-title":"Post-exposure lopinavir-ritonavir prophylaxis versus surveillance for individuals exposed to SARS-CoV-2: the COPEP pragmatic open-label, cluster randomized trial","volume":"42","author":"Labhardt","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"4","key":"2024062715541743000_ciac724-B70","doi-asserted-by":"crossref","first-page":"e216468","DOI":"10.1001\/jamanetworkopen.2021.6468","article-title":"Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with COVID-19: the TOGETHER randomized clinical trial","volume":"4","author":"Reis","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"19","key":"2024062715541743000_ciac724-B71","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"issue":"10259","key":"2024062715541743000_ciac724-B72","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)32013-4","article-title":"Lopinavir\u2013ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"396","author":"RECOVERY Collaborative Group;","year":"2020","journal-title":"Lancet"},{"key":"2024062715541743000_ciac724-B73","author":"World Health Organization"},{"issue":"6","key":"2024062715541743000_ciac724-B74","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1164\/rccm.201706-1172OC","article-title":"Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome","volume":"197","author":"Arabi","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2024062715541743000_ciac724-B75","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jcv.2004.07.006","article-title":"Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients","volume":"31","author":"Lee","year":"2004","journal-title":"J Clin Virol"},{"issue":"3","key":"2024062715541743000_ciac724-B76","first-page":"179","article-title":"[Glucocorticoid-induced diabetes in severe acute respiratory syndrome: the impact of high dosage and duration of methylprednisolone therapy]","volume":"43","author":"Xiao","year":"2004","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"12","key":"2024062715541743000_ciac724-B77","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1097\/CCM.0000000000002710","article-title":"Emotional impact of End-of-life decisions on professional relationships in the ICU: an obstacle to collegiality?","volume":"45","author":"Laurent","year":"2017","journal-title":"Crit Care Med"},{"issue":"3","key":"2024062715541743000_ciac724-B78","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(19)30417-5","article-title":"Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial","volume":"8","author":"Villar","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"13","key":"2024062715541743000_ciac724-B79","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","volume":"324","author":"WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group;","year":"2020","journal-title":"JAMA"},{"key":"2024062715541743000_ciac724-B80","article-title":"Effect of dexamethasone in hospitalized patients with COVID-19 \u2013 preliminary report","author":"Horby","year":"2020","journal-title":"medRxiv,"},{"key":"2024062715541743000_ciac724-B81","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jama.2020.17021","article-title":"Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial","volume":"324","author":"Tomazini","year":"2020","journal-title":"JAMA"},{"key":"2024062715541743000_ciac724-B82","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1001\/jama.2020.16761","article-title":"Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial","volume":"324","author":"Dequin","year":"2020","journal-title":"JAMA"},{"key":"2024062715541743000_ciac724-B83","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.2020.17022","article-title":"Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial","volume":"324","author":"Writing Committee for the REMAP-CAP Investigators;","year":"2020","journal-title":"JAMA"},{"key":"2024062715541743000_ciac724-B84","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/aas.13673","article-title":"Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan","volume":"64","author":"Petersen","year":"2020","journal-title":"Acta Anaesthesiol Scand"},{"key":"2024062715541743000_ciac724-B85","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1093\/cid\/ciaa1177","article-title":"Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial","volume":"72","author":"Jeronimo","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024062715541743000_ciac724-B86","article-title":"GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia","author":"Corral-Gudino","year":"2020","journal-title":"medRxiv,"},{"key":"2024062715541743000_ciac724-B87","article-title":"Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia","author":"Salton","year":"2020","journal-title":"medRxiv,"},{"key":"2024062715541743000_ciac724-B88","article-title":"Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China","author":"Wang","year":"2020","journal-title":"medRxiv,"},{"issue":"7","key":"2024062715541743000_ciac724-B89","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2024062715541743000_ciac724-B90","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01168-20","article-title":"Impact of glucocorticoid treatment in SARS-CoV-2 infection mortality: a retrospective controlled cohort study.","author":"Fernandez-Cruz","year":"2020"},{"key":"2024062715541743000_ciac724-B91","article-title":"Adjuvant corticosteroid therapy for critically ill patients with COVID-19","author":"Lu","year":"2020","journal-title":"medRxiv,"},{"issue":"5","key":"2024062715541743000_ciac724-B92","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/SHK.0000000000001574","article-title":"Effects of corticosteroid treatment for non-severe COVID-19 pneumonia: a propensity score-based analysis","volume":"54","author":"Yuan","year":"2020","journal-title":"Shock"},{"issue":"9203","key":"2024062715541743000_ciac724-B93","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0140-6736(99)06290-X","article-title":"Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment","volume":"355","author":"Henzen","year":"2000","journal-title":"Lancet"},{"issue":"7","key":"2024062715541743000_ciac724-B94","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7326\/M15-0715","article-title":"Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis","volume":"163","author":"Siemieniuk","year":"2015","journal-title":"Ann Intern Med"},{"issue":"10303","key":"2024062715541743000_ciac724-B95","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0140-6736(21)01744-X","article-title":"Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial","volume":"398","author":"Yu","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"2024062715541743000_ciac724-B96","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamainternmed.2021.6759","article-title":"Efficacy of inhaled ciclesonide for outpatient treatment of adolescents and adults with symptomatic COVID-19: a randomized clinical trial","volume":"182","author":"Clemency","year":"2022","journal-title":"JAMA Intern Med"},{"key":"2024062715541743000_ciac724-B97","article-title":"Inhaled and intranasal ciclesonide for the treatment of COVID-19 in adult outpatients: cONTAIN phase II randomised controlled trial","volume":"375","author":"Ezer","year":"2021","journal-title":"BMJ"},{"issue":"16","key":"2024062715541743000_ciac724-B98","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.3390\/jcm10163545","article-title":"Ciclesonide inhaler treatment for mild-to-moderate COVID-19: a randomized, open-label, phase 2 trial","volume":"10","author":"Song","year":"2021","journal-title":"J Clin Med"},{"issue":"7","key":"2024062715541743000_ciac724-B99","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S2213-2600(21)00160-0","article-title":"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial","volume":"9","author":"Ramakrishnan","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"8","key":"2024062715541743000_ciac724-B100","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19","volume":"384","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"N Engl J Med"},{"key":"2024062715541743000_ciac724-B101","doi-asserted-by":"publisher","first-page":"e01648-20","DOI":"10.1128\/JVI.01648-20","article-title":"The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells","volume":"95","author":"Matsuyama","year":"2020","journal-title":"J Virol"},{"issue":"1","key":"2024062715541743000_ciac724-B102","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1164\/rccm.202003-0821OC","article-title":"COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids","volume":"202","author":"Peters","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"2024062715541743000_ciac724-B103","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/QAI.0b013e31829260d6","article-title":"Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone","volume":"63","author":"Boyd","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"2024062715541743000_ciac724-B104","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest"},{"key":"2024062715541743000_ciac724-B105","first-page":"104","article-title":"[Coagulation and anticoagulation systems of the blood in allergic diseases]","volume":"9","author":"Kalikshtein","year":"1988","journal-title":"Sov Med"},{"key":"2024062715541743000_ciac724-B106","article-title":"Interleukin-6 receptor antagonists in critically ill patients with COVID-19\u2014preliminary report","author":"REMAP-CAP Investigators;","year":"2021","journal-title":"medRxiv,"},{"issue":"1","key":"2024062715541743000_ciac724-B107","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial","volume":"181","author":"Hermine","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"10285","key":"2024062715541743000_ciac724-B108","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial","volume":"397","author":"Horby","year":"2021","journal-title":"Lancet"},{"key":"2024062715541743000_ciac724-B109","article-title":"Tocilizumab in hospitalized patients with COVID-19 pneumonia","author":"Rosas","year":"2020","journal-title":"medRxiv,"},{"issue":"1","key":"2024062715541743000_ciac724-B110","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with COVID-19 pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2024062715541743000_ciac724-B111","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial","volume":"181","author":"Salvarani","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2024062715541743000_ciac724-B112","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with COVID-19","volume":"383","author":"Stone","year":"2020","journal-title":"N Engl J Med"},{"key":"2024062715541743000_ciac724-B113","doi-asserted-by":"crossref","first-page":"n84","DOI":"10.1136\/bmj.n84","article-title":"Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial","volume":"372","author":"Veiga","year":"2021","journal-title":"BMJ"},{"issue":"5","key":"2024062715541743000_ciac724-B114","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2213-2600(21)00099-0","article-title":"Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Lescure","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024062715541743000_ciac724-B115","article-title":"A randomized placebo-controlled trial of sarilumab in hospitalized patients with COVID-19","author":"Sivapalasingam","year":"2021","journal-title":"medRxiv,"},{"key":"2024062715541743000_ciac724-B116","article-title":"Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalized patients with COVID-19: a network meta-analysis","author":"Godolphin","year":"2021","journal-title":"medRxiv,"},{"issue":"6","key":"2024062715541743000_ciac724-B117","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0003134820926481","article-title":"Gastrointestinal perforation after treatment with tocilizumab: an unexpected consequence of COVID-19 pandemic","volume":"86","author":"Rojo","year":"2020","journal-title":"Am Surg"},{"key":"2024062715541743000_ciac724-B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.cireng.2021.01.002","article-title":"Intestinal perforation in patient with COVID-19 infection treated with tocilizumab and corticosteroids. Report of a clinical case","volume":"99","author":"Gonzalvez Guardiola","year":"2021","journal-title":"Cir Esp"},{"key":"2024062715541743000_ciac724-B119","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001273","article-title":"Tocilizumab-associated bowel perforation in SARS-CoV-2 infection","author":"Ranchal","year":"2020","journal-title":"Am J Ther"},{"issue":"1","key":"2024062715541743000_ciac724-B120","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2020-000484","article-title":"Bowel ulceration following tocilizumab administration in a COVID-19 patient","volume":"7","author":"Bruce-Hickman","year":"2020","journal-title":"BMJ Open Gastroenterol"},{"issue":"8","key":"2024062715541743000_ciac724-B121","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2024062715541743000_ciac724-B122","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa954","article-title":"Tocilizumab for treatment of mechanically ventilated patients with COVID-19","volume":"73","author":"Somers","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2024062715541743000_ciac724-B123","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial","volume":"324","author":"Li","year":"2020","journal-title":"JAMA"},{"key":"2024062715541743000_ciac724-B124","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1038\/s41467-021-23469-2","article-title":"Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection","volume":"12","author":"Gharbharan","year":"2021","journal-title":"Nat Commun"},{"key":"2024062715541743000_ciac724-B125","doi-asserted-by":"crossref","first-page":"9927","DOI":"10.1038\/s41598-021-89444-5","article-title":"Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease","volume":"11","author":"AlQahtani","year":"2021","journal-title":"Sci Rep"},{"key":"2024062715541743000_ciac724-B126","doi-asserted-by":"publisher","DOI":"10.1172\/JCI152740","article-title":"A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia","volume":"131","author":"Avenda\u00f1o-Sol\u00e0","year":"2021","journal-title":"J Clin Invest"},{"key":"2024062715541743000_ciac724-B127","article-title":"Prevention of severe COVID-19 in the elderly by early high-titer plasma","author":"Libster","year":"2020","journal-title":"medRxiv,"},{"key":"2024062715541743000_ciac724-B128","article-title":"Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience","author":"Joyner","year":"2020","journal-title":"medRxiv,"},{"key":"2024062715541743000_ciac724-B129","author":"Expanded Access to Convalescent Plasma for the Treatment of Patients Team"},{"key":"2024062715541743000_ciac724-B130","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01488-2","article-title":"Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial","author":"B\u00e9gin","year":"2021","journal-title":"Nat Med."},{"key":"2024062715541743000_ciac724-B131","author":"US Food and Drug Administration"},{"key":"2024062715541743000_ciac724-B132","author":"US Food and Drug Administration"},{"key":"2024062715541743000_ciac724-B133","article-title":"Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial","author":"Ray","year":"2020","journal-title":"medRxiv,"},{"issue":"7","key":"2024062715541743000_ciac724-B134","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMoa2031304","article-title":"A randomized trial of convalescent plasma in COVID-19 severe pneumonia","volume":"384","author":"Simonovich","year":"2021","journal-title":"N Engl J Med"},{"key":"2024062715541743000_ciac724-B135","first-page":"m4232","article-title":"Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial)","volume":"371","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"issue":"13","key":"2024062715541743000_ciac724-B136","doi-asserted-by":"crossref","first-page":"e150646","DOI":"10.1172\/JCI150646","article-title":"A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19","volume":"131","author":"O\u2019Donnell","year":"2021","journal-title":"J Clin Invest"},{"issue":"10289","key":"2024062715541743000_ciac724-B137","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","article-title":"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"2024062715541743000_ciac724-B138","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003415","article-title":"Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: a randomized phase II clinical trial","volume":"18","author":"Balcells","year":"2021","journal-title":"PLoS Med"},{"issue":"9","key":"2024062715541743000_ciac724-B139","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.mayocp.2020.06.028","article-title":"Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients","volume":"95","author":"Joyner","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"21","key":"2024062715541743000_ciac724-B140","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1056\/NEJMoa2103784","article-title":"Early convalescent plasma for high-risk outpatients with COVID-19","volume":"385","author":"Korley","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"2024062715541743000_ciac724-B141","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa2033700","article-title":"Early high-titer plasma therapy to prevent severe COVID-19 in older adults","volume":"384","author":"Libster","year":"2021","journal-title":"N Engl J Med"},{"key":"2024062715541743000_ciac724-B142","article-title":"Randomized controlled trial of early outpatient COVID-19 treatment with high-titer convalescent plasma","author":"Sullivan","year":"21  2021","journal-title":"medRxiv,"},{"issue":"8","key":"2024062715541743000_ciac724-B143","doi-asserted-by":"crossref","first-page":"102898","DOI":"10.1016\/j.isci.2021.102898","article-title":"Effect of time and titer in convalescent plasma therapy for COVID-19","volume":"24","author":"de Candia","year":"2021","journal-title":"iScience"},{"key":"2024062715541743000_ciac724-B144","author":"US Food and Drug Administration"},{"issue":"11","key":"2024062715541743000_ciac724-B145","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa2031893","article-title":"Convalescent plasma antibody levels and the risk of death from COVID-19","volume":"384","author":"Joyner","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2024062715541743000_ciac724-B146","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ajpath.2020.10.008","article-title":"Significantly decreased mortality in a large cohort of coronavirus disease 2019 (COVID-19) patients transfused early with convalescent plasma containing high-titer anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein IgG","volume":"191","author":"Salazar","year":"2021","journal-title":"Am J Pathol"},{"issue":"20","key":"2024062715541743000_ciac724-B147","doi-asserted-by":"crossref","DOI":"10.1172\/JCI151788","article-title":"Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19","volume":"131","author":"Arnold Egloff","year":"2021","journal-title":"J Clin Invest"},{"issue":"8","key":"2024062715541743000_ciac724-B148","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/jamaoncol.2021.1799","article-title":"Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19","volume":"7","author":"Thompson","year":"2021","journal-title":"JAMA Oncol"},{"issue":"7","key":"2024062715541743000_ciac724-B149","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/CCM.0000000000005066","article-title":"Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York: a double-blind randomized trial","volume":"49","author":"Bennett-Guerrero","year":"2021","journal-title":"Crit Care Med"},{"issue":"5","key":"2024062715541743000_ciac724-B150","article-title":"Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial","volume":"58","author":"Sekine","year":"2021","journal-title":"Eur Respir J"},{"issue":"8","key":"2024062715541743000_ciac724-B151","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1007\/s11739-021-02734-8","article-title":"A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm","volume":"16","author":"Pouladzadeh","year":"2021","journal-title":"Intern Emerg Med"},{"issue":"17","key":"2024062715541743000_ciac724-B152","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.2021.18178","article-title":"Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial","volume":"326","author":"Writing Committee for the REMAP-CAP Investigators","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"2024062715541743000_ciac724-B153","article-title":"Efficacy of convalescent plasma for treatment of COVID-19 in Uganda","volume":"8","author":"Kirenga","year":"2021","journal-title":"BMJ Open Respir Res"},{"key":"2024062715541743000_ciac724-B154","article-title":"High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID","author":"K\u00f6rper","year":"10  2021","journal-title":"medRxiv,"},{"key":"2024062715541743000_ciac724-B155","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01724-2021","article-title":"Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma","volume":"59","author":"Devos","year":"2022","journal-title":"Eur Respir J"},{"key":"2024062715541743000_ciac724-B156","doi-asserted-by":"crossref","first-page":"43395","DOI":"10.1038\/srep43395","article-title":"GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses","volume":"7","author":"Lo","year":"2017","journal-title":"Sci Rep"},{"key":"2024062715541743000_ciac724-B157","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci Transl Med"},{"issue":"7594","key":"2024062715541743000_ciac724-B158","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"issue":"7824","key":"2024062715541743000_ciac724-B159","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2","volume":"585","author":"Williamson","year":"2020","journal-title":"Nature"},{"issue":"4","key":"2024062715541743000_ciac724-B160","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe COVID-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl J Med"},{"issue":"19","key":"2024062715541743000_ciac724-B161","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19\u2014final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"issue":"10236","key":"2024062715541743000_ciac724-B162","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"2024062715541743000_ciac724-B163","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 days in patients with severe COVID-19","volume":"383","author":"Goldman","year":"2020","journal-title":"N Engl J Med"},{"key":"2024062715541743000_ciac724-B164","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-047803","article-title":"Compassionate use of remdesivir in children with severe COVID-19","volume":"147","author":"Goldman","year":"2021","journal-title":"Pediatrics"},{"key":"2024062715541743000_ciac724-B165","author":"Gilead Sciences, Inc"},{"key":"2024062715541743000_ciac724-B166","author":"Borrell"},{"issue":"3","key":"2024062715541743000_ciac724-B167","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1053\/j.gastro.2020.05.053","article-title":"Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study","volume":"159","author":"Freedberg","year":"2020","journal-title":"Gastroenterology"},{"issue":"5","key":"2024062715541743000_ciac724-B168","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/gutjnl-2022-326952","article-title":"Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial","volume":"71","author":"Brennan","year":"2022","journal-title":"Gut"},{"issue":"2","key":"2024062715541743000_ciac724-B169","first-page":"e22404","article-title":"Efficacy of oral famotidine in patients hospitalized with severe acute respiratory syndrome coronavirus 2","volume":"14","author":"Pahwani","year":"2022","journal-title":"Cureus"},{"key":"2024062715541743000_ciac724-B170","author":"US Food and Drug Administration"},{"key":"2024062715541743000_ciac724-B171","article-title":"LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection","author":"Jones","year":"9  2020","journal-title":"bioRxiv,"},{"issue":"6520","key":"2024062715541743000_ciac724-B172","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1126\/science.abe2402","article-title":"REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters","volume":"370","author":"Baum","year":"2020","journal-title":"Science"},{"issue":"1","key":"2024062715541743000_ciac724-B173","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jama.2021.8828","article-title":"Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial","volume":"326","author":"Cohen","year":"2021","journal-title":"JAMA"},{"key":"2024062715541743000_ciac724-B174","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","volume-title":"N Engl J Med","author":"Levin","year":"2022"},{"key":"2024062715541743000_ciac724-B175","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","article-title":"Subcutaneous REGEN-COV antibody combination to prevent COVID-19","volume":"385","author":"O'Brien","year":"2021","journal-title":"N Engl J Med"},{"key":"2024062715541743000_ciac724-B176","author":"US Food and Drug Administration"},{"key":"2024062715541743000_ciac724-B177","author":"US Food and Drug Administration"},{"key":"2024062715541743000_ciac724-B178","author":"US Food and Drug Administration"},{"key":"2024062715541743000_ciac724-B179","article-title":"Susceptibility of SARS-CoV-2 omicron variants to therapeutic monoclonal antibodies: systematic review and meta-analysis","author":"Tao","year":"2022","journal-title":"Preprints"},{"issue":"3","key":"2024062715541743000_ciac724-B180","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19","volume":"384","author":"Chen","year":"2021","journal-title":"N Engl J Med"},{"key":"2024062715541743000_ciac724-B181","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa2033130","article-title":"A neutralizing monoclonal antibody for hospitalized patients with COVID-19","volume":"384","author":"ACTIV-3\/TICO LY-CoV555 Study Group","year":"2021","journal-title":"N Engl J Med"},{"key":"2024062715541743000_ciac724-B182","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus etesevimab in mild or moderate COVID-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"2024062715541743000_ciac724-B183","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jama.2022.2832","article-title":"Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial","volume":"327","author":"Gupta","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"2024062715541743000_ciac724-B184","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"2024062715541743000_ciac724-B185","author":"Regeneron Pharmaceuticals, Inc"},{"key":"2024062715541743000_ciac724-B186","author":"US Food and Drug Administration"},{"key":"2024062715541743000_ciac724-B187","author":"US Food and Drug Administration"},{"key":"2024062715541743000_ciac724-B188","author":"US Food and Drug Administration"},{"key":"2024062715541743000_ciac724-B189","author":"US Food and Drug Administration"},{"issue":"5","key":"2024062715541743000_ciac724-B190","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2021.24939","article-title":"Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized clinical trial","volume":"327","author":"O'Brien","year":"2022","journal-title":"JAMA"},{"key":"2024062715541743000_ciac724-B191","author":"US Food and Drug Administration"},{"key":"2024062715541743000_ciac724-B192","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jclinepi.2019.11.019","article-title":"Grading of Recommendations Assessment, Development, and Evaluations (GRADE) notes: extremely serious, GRADE's terminology for rating down by three levels","volume":"120","author":"Piggott","year":"2020","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"2024062715541743000_ciac724-B193","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/phar.2438","article-title":"Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"4","key":"2024062715541743000_ciac724-B194","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1172\/JCI89857","article-title":"Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects","volume":"127","author":"Bekerman","year":"2017","journal-title":"J Clin Invest"},{"issue":"8","key":"2024062715541743000_ciac724-B195","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1128\/JVI.02705-14","article-title":"AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets","volume":"89","author":"Neveu","year":"2015","journal-title":"J Virol"},{"issue":"10223","key":"2024062715541743000_ciac724-B196","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"2024062715541743000_ciac724-B197","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jinf.2020.04.017","article-title":"Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact","volume":"81","author":"Cantini","year":"2020","journal-title":"J Infect"},{"key":"2024062715541743000_ciac724-B198","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa879","article-title":"Use of baricitinib in patients with moderate and severe COVID-19","volume":"72","author":"Titanji","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2024062715541743000_ciac724-B199","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/rheumatology\/keaa587","article-title":"Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study","volume":"60","author":"Rodriguez-Garcia","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"2024062715541743000_ciac724-B200","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jinf.2020.06.052","article-title":"Beneficial impact of baricitinib in COVID-19 moderate pneumonia; multicentre study","volume":"81","author":"Cantini","year":"2020","journal-title":"J Infect"},{"key":"2024062715541743000_ciac724-B201","article-title":"Baricitinib plus standard of care for hospitalized adults with COVID-19","volume-title":"medRxiv,","author":"Marconi","year":"3  2021"},{"key":"2024062715541743000_ciac724-B202"},{"issue":"3","key":"2024062715541743000_ciac724-B203","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40257-021-00602-x","article-title":"Extended safety analysis of baricitinib 2 mg in adult patients with atopic dermatitis: an integrated analysis from eight randomized clinical trials","volume":"22","author":"King","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"2024062715541743000_ciac724-B204","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/annrheumdis-2019-216852","article-title":"Infections in baricitinib clinical trials for patients with active rheumatoid arthritis","volume":"79","author":"Winthrop","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"2024062715541743000_ciac724-B205","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2020006000","article-title":"COVID-19 and its implications for thrombosis and anticoagulation","volume":"135","author":"Connors","year":"2020","journal-title":"Blood"},{"key":"2024062715541743000_ciac724-B206","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with COVID-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"2024062715541743000_ciac724-B207","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024062715541743000_ciac724-B208","article-title":"Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis","author":"RECOVERY Collaborative Group","year":"3  2022","journal-title":"medRxiv,"},{"issue":"4","key":"2024062715541743000_ciac724-B209","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S2213-2600(22)00006-6","article-title":"Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial","volume":"10","author":"Ely","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"5","key":"2024062715541743000_ciac724-B210","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2101643","article-title":"Tofacitinib in patients hospitalized with COVID-19 pneumonia","volume":"385","author":"Guimaraes","year":"2021","journal-title":"N Engl J Med"},{"key":"2024062715541743000_ciac724-B211","author":"US Food and Drug Administration"},{"key":"2024062715541743000_ciac724-B212","author":"US Food and Drug Administration"},{"key":"2024062715541743000_ciac724-B213","author":"US Food and Drug Administration"},{"key":"2024062715541743000_ciac724-B214","author":"US Food and Drug Administration"},{"key":"2024062715541743000_ciac724-B215","doi-asserted-by":"crossref","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res"},{"key":"2024062715541743000_ciac724-B216","doi-asserted-by":"crossref","first-page":"104805","DOI":"10.1016\/j.antiviral.2020.104805","article-title":"Ivermectin and COVID-19: a report in antiviral research, widespread interest, an FDA warning, two letters to the editor and the authors\u2019 responses","volume":"178","author":"Bray","year":"2020","journal-title":"Antiviral Res"},{"issue":"11","key":"2024062715541743000_ciac724-B217","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00011-008-8007-8","article-title":"Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice","volume":"57","author":"Zhang","year":"2008","journal-title":"Inflamm Res"},{"issue":"6","key":"2024062715541743000_ciac724-B218","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00011-011-0307-8","article-title":"Anti-inflammatory effects of ivermectin in mouse model of allergic asthma","volume":"60","author":"Yan","year":"2011","journal-title":"Inflamm Res"},{"key":"2024062715541743000_ciac724-B219","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijid.2020.11.191","article-title":"A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness","volume":"103","author":"Ahmed","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"09","key":"2024062715541743000_ciac724-B220","first-page":"31","article-title":"Effectiveness of ivermectin in SARS-CoV-2\/COVID-19 patients","volume":"9","author":"Chachar","year":"2020","journal-title":"Int J Sci"},{"key":"2024062715541743000_ciac724-B221","doi-asserted-by":"crossref","first-page":"100720","DOI":"10.1016\/j.eclinm.2020.100720","article-title":"The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial","volume":"32","author":"Chaccour","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2024062715541743000_ciac724-B222","article-title":"Controlled randomized clinical trial on using ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq","author":"Hashim","year":"27  2020","journal-title":"medRxiv,"},{"issue":"2","key":"2024062715541743000_ciac724-B223","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3329\/imcjms.v14i2.52826","article-title":"Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study","volume":"14","author":"Podder","year":"2021","journal-title":"IMC J Med Sci"},{"key":"2024062715541743000_ciac724-B224","article-title":"Efficacy of ivermectin in COVID-19 patients with mild to moderate disease","author":"Bukhari","year":"5  2021","journal-title":"medRxiv,"},{"key":"2024062715541743000_ciac724-B225","article-title":"Ivermectin as a potential treatment for mild to moderate COVID-19\u2013A double blind randomized placebo-controlled trial","author":"Ravikirti","year":"9  2021","journal-title":"medRxiv,"},{"issue":"14","key":"2024062715541743000_ciac724-B226","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1001\/jama.2021.3071","article-title":"Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial","volume":"325","author":"Lopez-Medina","year":"2021","journal-title":"JAMA"},{"key":"2024062715541743000_ciac724-B227","article-title":"Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial","author":"Mohan","year":"2  2021","journal-title":"Res Square,"},{"issue":"2","key":"2024062715541743000_ciac724-B228","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/idr14020020","article-title":"Efficacy and safety of ivermectin and hydroxychloroquine in patients with severe COVID-19: a randomized controlled trial","volume":"14","author":"Gonzalez","year":"2022","journal-title":"Infect Dis Rep"},{"key":"2024062715541743000_ciac724-B229","doi-asserted-by":"crossref","first-page":"100959","DOI":"10.1016\/j.eclinm.2021.100959","article-title":"Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial","volume":"37","author":"Krolewiecki","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"10","key":"2024062715541743000_ciac724-B230","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.1002\/jmv.27122","article-title":"Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: a randomized controlled study","volume":"93","author":"Abd-Elsalam","year":"2021","journal-title":"J Med Virol"},{"key":"2024062715541743000_ciac724-B231","doi-asserted-by":"crossref","DOI":"10.1177\/03000605211013550","article-title":"Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial","volume":"49","author":"Mahmud","year":"2021","journal-title":"J Int Med Res"},{"issue":"1","key":"2024062715541743000_ciac724-B232","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1186\/s12879-021-06348-5","article-title":"Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial","volume":"21","author":"Vallejos","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2024062715541743000_ciac724-B233","article-title":"Favorable outcome on viral load and culture viability using ivermectin in early treatment of non-hospitalized patients with mild COVID-19, A double-blind, randomized placebo-controlled trial","author":"Biber","year":"31  2021","journal-title":"medRxiv,"},{"issue":"18","key":"2024062715541743000_ciac724-B234","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1056\/NEJMoa2115869","article-title":"Effect of early treatment with ivermectin among patients with COVID-19","volume":"386","author":"Reis","year":"2022","journal-title":"N Engl J Med"},{"issue":"Special Issue","key":"2024062715541743000_ciac724-B235","first-page":"87","article-title":"The effect of ivermectin on reducing viral symptoms in patients with mild COVID-19","volume":"84","author":"Abbas","year":"2022","journal-title":"Indian J Pharm Sci"},{"issue":"2","key":"2024062715541743000_ciac724-B236","doi-asserted-by":"crossref","first-page":"106516","DOI":"10.1016\/j.ijantimicag.2021.106516","article-title":"High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial","volume":"59","author":"Buonfrate","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2024062715541743000_ciac724-B237","article-title":"Ivermectin for treatment of mild-to-moderate COVID-19 in the outpatient setting: a decentralized, placebo-controlled, randomized, platform clinical trial","author":"Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group;","year":"12  2022","journal-title":"medRxiv,"},{"issue":"4","key":"2024062715541743000_ciac724-B238","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/jamainternmed.2022.0189","article-title":"Efficacy of ivermectin treatment on disease progression among adults with mild to moderate COVID-19 and comorbidities: the I-TECH randomized clinical trial","volume":"182","author":"Lim","year":"2022","journal-title":"JAMA Intern Med"},{"key":"2024062715541743000_ciac724-B239","article-title":"Efficacy and safety of ivermectin in the treatment of mild-to-moderate COVID-19 infection: a randomized, double blind, placebo, controlled trial","author":"Manomaipiboon","year":"2  2022","journal-title":"Res Square,"},{"key":"2024062715541743000_ciac724-B240","article-title":"Ivermectin shows clinical benefits in mild to moderate Covid19 disease: a randomised controlled double blind dose response study in Lagos","author":"Babalola","year":"6  2021","journal-title":"medRxiv,"},{"key":"2024062715541743000_ciac724-B241","doi-asserted-by":"publisher","DOI":"10.4103\/1995-7645.318304","article-title":"Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: a randomized multi-center clinical trial.","volume":"14","author":"Niaee","year":"2021","journal-title":"Asian Pac J Trop Biomed"},{"key":"2024062715541743000_ciac724-B242","author":"Rezaie"},{"issue":"2","key":"2024062715541743000_ciac724-B243","first-page":"OC27","article-title":"Use of ivermectin as a potential chemoprophylaxis for COVID-19 in Egypt: a randomized clinical trial","volume":"15","author":"Shoumann","year":"2021","journal-title":"J Clin Diagn Res"},{"key":"2024062715541743000_ciac724-B244","author":"Peral de Bruno"},{"key":"2024062715541743000_ciac724-B245","author":"Raad"},{"key":"2024062715541743000_ciac724-B246","doi-asserted-by":"publisher","first-page":"eaau5266","DOI":"10.1126\/scitranslmed.aau5266","article-title":"Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis","volume":"11","author":"Rosen","year":"2019","journal-title":"Sci Transl Med"},{"issue":"7816","key":"2024062715541743000_ciac724-B247","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"2024062715541743000_ciac724-B248","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejphar.2014.01.064","article-title":"Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells","volume":"727","author":"Ishima","year":"2014","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"2024062715541743000_ciac724-B249","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1440-1819.2011.02241.x","article-title":"Coagulation activation and fibrinolysis impairment are reduced in patients with anxiety and depression when medicated with serotonergic antidepressants","volume":"65","author":"Geiser","year":"2011","journal-title":"Psychiatry Clin Neurosci"},{"issue":"6","key":"2024062715541743000_ciac724-B250","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2012-06-437392","article-title":"Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice","volume":"121","author":"Duerschmied","year":"2013","journal-title":"Blood"},{"issue":"22","key":"2024062715541743000_ciac724-B251","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.2020.22760","article-title":"Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial","volume":"324","author":"Lenze","year":"2020","journal-title":"JAMA"},{"key":"2024062715541743000_ciac724-B252","first-page":"e42","article-title":"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the together randomised, platform clinical trial","volume":"10","author":"Reis","year":"2021","journal-title":"Lancet"},{"key":"2024062715541743000_ciac724-B253","author":"US Food and Drug Administration"},{"key":"2024062715541743000_ciac724-B254","author":"US Food and Drug Administration"},{"key":"2024062715541743000_ciac724-B255","author":"US Food and Drug Administration"},{"issue":"5","key":"2024062715541743000_ciac724-B256","doi-asserted-by":"crossref","first-page":"e02428","DOI":"10.1128\/AAC.02428-20","article-title":"Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2024062715541743000_ciac724-B257","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med."},{"key":"2024062715541743000_ciac724-B258","doi-asserted-by":"publisher","first-page":"eabl7430","DOI":"10.1126\/scitranslmed.abl7430","article-title":"A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus","volume":"14","author":"Fischer","year":"2022","journal-title":"Sci Transl Med"},{"issue":"3","key":"2024062715541743000_ciac724-B259","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s11926-002-0073-2","article-title":"Update on colchicine and its mechanism of action","volume":"4","author":"Molad","year":"2002","journal-title":"Curr Rheumatol Rep"},{"issue":"10","key":"2024062715541743000_ciac724-B260","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.clinthera.2014.07.017","article-title":"Mechanism of action of colchicine in the treatment of gout","volume":"36","author":"Dalbeth","year":"2014","journal-title":"Clin Ther"},{"issue":"3","key":"2024062715541743000_ciac724-B261","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1084\/jem.171.3.715","article-title":"Downregulation of tumor necrosis factor receptors on macrophages and endothelial cells by microtubule depolymerizing agents","volume":"171","author":"Ding","year":"1990","journal-title":"J Exp Med"},{"issue":"7081","key":"2024062715541743000_ciac724-B262","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"issue":"2","key":"2024062715541743000_ciac724-B263","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1172\/JCI118147","article-title":"Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils","volume":"96","author":"Cronstein","year":"1995","journal-title":"J Clin Invest"},{"issue":"2","key":"2024062715541743000_ciac724-B264","doi-asserted-by":"crossref","first-page":"15","DOI":"10.18087\/cardio.2021.2.n1560","article-title":"Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study","volume":"61","author":"Mareev","year":"2021","journal-title":"Kardiologiia"},{"key":"2024062715541743000_ciac724-B265","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/2129006","article-title":"Efficacy of colchicine and budesonide in improvement outcomes of patients with coronavirus infection 2019 in Damascus, Syria: a randomized control trial","volume":"2021","author":"Alsultan","year":"2021","journal-title":"Interdiscip Perspect Infect Dis"},{"issue":"1","key":"2024062715541743000_ciac724-B266","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001455","article-title":"Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial","volume":"7","author":"Lopes","year":"2021","journal-title":"RMD Open"},{"issue":"12","key":"2024062715541743000_ciac724-B267","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.41328","article-title":"Effect of colchicine vs usual care alone on intubation and 28-day mortality in patients hospitalized with COVID-19: a randomized clinical trial","volume":"4","author":"Diaz","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2024062715541743000_ciac724-B268","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.13136","article-title":"Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial","volume":"3","author":"Deftereos","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"12","key":"2024062715541743000_ciac724-B269","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S2213-2600(21)00435-5","article-title":"Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"9","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024062715541743000_ciac724-B270","doi-asserted-by":"crossref","first-page":"101242","DOI":"10.1016\/j.eclinm.2021.101242","article-title":"Effectiveness of rosuvastatin plus colchicine, emtricitabine\/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial","volume":"43","author":"Gait\u00e1n-Duarte","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2024062715541743000_ciac724-B271","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.2147\/IJGM.S329810","article-title":"Colchicine in recently hospitalized patients with COVID-19: a randomized controlled trial (COL-COVID)","volume":"14","author":"Pascual-Figal","year":"2021","journal-title":"Int J Gen Med"},{"issue":"1","key":"2024062715541743000_ciac724-B272","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11606-021-07203-8","article-title":"Colchicine is safe though ineffective in the treatment of severe COVID-19: a randomized clinical trial (COLCHIVID)","volume":"37","author":"Absalon-Aguilar","year":"2022","journal-title":"J Gen Intern Med"},{"key":"2024062715541743000_ciac724-B273","first-page":"103593","article-title":"Randomized controlled trial of colchicine add on to the standard therapy in moderate and severe Coronavirus Disease-19 infection","volume":"77","author":"Gorial","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"2024062715541743000_ciac724-B274","article-title":"Efficacy of colchicine in non-hospitalized patients with COVID-19","author":"Tardif","year":"27  2021","journal-title":"medRxiv,"},{"key":"2024062715541743000_ciac724-B275","article-title":"Colchicine for COVID-19 in adults in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial","author":"Dorward","year":"23  2021","journal-title":"medRxiv,"},{"key":"2024062715541743000_ciac724-B276","author":"Centers for Disease Control and Prevention"},{"issue":"6","key":"2024062715541743000_ciac724-B277","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis","volume":"326","author":"WHO Rapid Evidence Appraisal for COVID-19 Therapies Working Group","year":"2021","journal-title":"JAMA"},{"key":"2024062715541743000_ciac724-B278","article-title":"Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised placebo-controlled trial","author":"Ely","year":"12  2021","journal-title":"medRxiv,"},{"issue":"10223","key":"2024062715541743000_ciac724-B279","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"issue":"10229","key":"2024062715541743000_ciac724-B280","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"2024062715541743000_ciac724-B281","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.rce.2020.07.003","article-title":"Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 registry","volume":"220","author":"Rojo","year":"2020","journal-title":"Rev Clin Esp (Barc)"},{"key":"2024062715541743000_ciac724-B282","doi-asserted-by":"publisher","first-page":"m1996","DOI":"10.1136\/bmj.m1996","article-title":"Characterization and clinical course of 1000 patients with COVID-19 in New York: retrospective case series","volume":"369","author":"Argenziano","year":"2020","journal-title":"BMJ"},{"issue":"10","key":"2024062715541743000_ciac724-B283","doi-asserted-by":"crossref","first-page":"e533","DOI":"10.1093\/cid\/ciaa1239","article-title":"Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital cohort study","volume":"72","author":"Vaughn","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2024062715541743000_ciac724-B284","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/jac\/dkaa563","article-title":"Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics","volume":"76","author":"Mason","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2024062715541743000_ciac724-B285","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlaa071","article-title":"Bacterial pneumonia coinfection and antimicrobial therapy duration in SARS-CoV-2 (COVID-19) infection","volume":"2","author":"Townsend","year":"2020","journal-title":"JAC Antimicrob Resist"},{"issue":"5","key":"2024062715541743000_ciac724-B286","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251340","article-title":"Inappropriate antibiotic use in the COVID-19 era: factors associated with inappropriate prescribing and secondary complications. Analysis of the registry SEMI-COVID","volume":"16","author":"Calderon-Parra","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"2024062715541743000_ciac724-B287","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa578","article-title":"Prevalence of co-infection at the time of hospital admission in COVID-19 patients, a multicenter study","volume":"8","author":"Karaba","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"2024062715541743000_ciac724-B288","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.cmi.2020.07.016","article-title":"Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis","volume":"26","author":"Langford","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"2024062715541743000_ciac724-B289","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/S2666-5247(20)30036-7","article-title":"Low rate of bacterial co-infection in patients with COVID-19","volume":"1","author":"Adler","year":"2020","journal-title":"Lancet Microbe"},{"issue":"10","key":"2024062715541743000_ciac724-B290","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.cmi.2020.06.025","article-title":"Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting","volume":"26","author":"Hughes","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"2024062715541743000_ciac724-B291","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cmi.2020.07.041","article-title":"Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study","volume":"27","author":"Garcia-Vidal","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"2024062715541743000_ciac724-B292","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01341-21","article-title":"Antibiotic use and bacterial infection among inpatients in the first wave of COVID-19: a retrospective cohort study of 64,691 patients","volume":"65","author":"Baghdadi","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2024062715541743000_ciac724-B293","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2021.148","article-title":"Hospital-acquired infections among adult patients admitted for coronavirus disease 2019 (COVID-19)","volume":"43","author":"Smith","year":"2022","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"9","key":"2024062715541743000_ciac724-B294","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s00134-020-06165-5","article-title":"Early bacterial co-infection in ARDS related to COVID-19","volume":"46","author":"Kreitmann","year":"2020","journal-title":"Intensive Care Med"},{"issue":"5","key":"2024062715541743000_ciac724-B295","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciaa762","article-title":"Bacterial pneumonia in COVID-19 critically ill patients: a case series","volume":"72","author":"Dudoignon","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024062715541743000_ciac724-B296","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2021.175","article-title":"The role of procalcitonin results in antibiotic decision-making in coronavirus disease 2019 (COVID-19)","volume":"43","author":"Fabre","year":"2022","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"2024062715541743000_ciac724-B297","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/cne.902680105","article-title":"Intracortical connections and their physiological correlates in the primary auditory cortex (AI) of the cat","volume":"268","author":"Matsubara","year":"1988","journal-title":"J Comp Neurol"},{"key":"2024062715541743000_ciac724-B298","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa524","article-title":"COVID-19, superinfections and antimicrobial development: what can we expect?","volume":"71","author":"Clancy","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024062715541743000_ciac724-B299","author":"Centers for Disease Control and Prevention"},{"issue":"24","key":"2024062715541743000_ciac724-B300","doi-asserted-by":"crossref","first-page":"759","DOI":"10.15585\/mmwr.mm6924e2","article-title":"Coronavirus disease 2019 case surveillance\u2014United States, January 22\u2013May 30, 2020","volume":"69","author":"Stokes","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"32","key":"2024062715541743000_ciac724-B301","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.15585\/mmwr.mm6932e3","article-title":"Hospitalization rates and characteristics of children aged &lt;18 years hospitalized with laboratory-confirmed COVID-19\u2014COVID-NET, 14 states, March 1\u2013July 25, 2020","volume":"69","author":"Kim","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"2024062715541743000_ciac724-B302","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1001\/jamapediatrics.2020.3988","article-title":"Clinical characteristics and viral RNA detection in children with coronavirus disease 2019 in the Republic of Korea","volume":"175","author":"Han","year":"2021","journal-title":"JAMA Pediatr"},{"issue":"10","key":"2024062715541743000_ciac724-B303","doi-asserted-by":"crossref","first-page":"e212025","DOI":"10.1001\/jamapediatrics.2021.2025","article-title":"Comparison of symptoms and RNA levels in children and adults with SARS-CoV-2 infection in the community setting","volume":"175","author":"Chung","year":"2021","journal-title":"JAMA Pediatr"},{"issue":"36","key":"2024062715541743000_ciac724-B304","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.15585\/mmwr.mm7036e2","article-title":"Hospitalizations associated with COVID-19 among children and adolescents\u2014COVID-NET, 14 states, March 1, 2020\u2013August 14, 2021","volume":"70","author":"Delahoy","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"36","key":"2024062715541743000_ciac724-B305","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.15585\/mmwr.mm7036e1","article-title":"Trends in COVID-19 cases, emergency department visits, and hospital admissions among children and adolescents aged 0\u201317 years\u2014United States, August 2020\u2013August 2021","volume":"70","author":"Siegel","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"2024062715541743000_ciac724-B306","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00431-020-03801-6","article-title":"COVID-19 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review of critically unwell children and the association with underlying comorbidities","volume":"180","author":"Williams","year":"2021","journal-title":"Eur J Pediatr"},{"issue":"9","key":"2024062715541743000_ciac724-B307","doi-asserted-by":"crossref","first-page":"e2875","DOI":"10.1093\/cid\/ciaa1693","article-title":"Severe acute respiratory syndrome coronavirus 2 infections among children in the biospecimens from respiratory virus-exposed kids (BRAVE Kids) study","volume":"73","author":"Hurst","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2024062715541743000_ciac724-B308","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jamapediatrics.2021.2770","article-title":"Association of age and pediatric household transmission of SARS-CoV-2 infection","volume":"175","author":"Paul","year":"2021","journal-title":"JAMA Pediatr"},{"issue":"5","key":"2024062715541743000_ciac724-B309","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.acap.2018.02.010","article-title":"Development and validation of the Pediatric Medical Complexity Algorithm (PMCA) Version 3.0","volume":"18","author":"Simon","year":"2018","journal-title":"Acad Pediatr"},{"issue":"39","key":"2024062715541743000_ciac724-B310","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.15585\/mmwr.mm6939e2","article-title":"COVID-19 trends among school-aged children\u2014United States, March 1\u2013September 19, 2020","volume":"69","author":"Leeb","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"2024062715541743000_ciac724-B311","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-042929","article-title":"Thirty-day outcomes of children and adolescents with COVID-19: an international experience","volume":"148","author":"Duarte-Salles","year":"2021","journal-title":"Pediatrics"},{"issue":"6","key":"2024062715541743000_ciac724-B312","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.11182","article-title":"Underlying medical conditions associated with severe COVID-19 illness among children","volume":"4","author":"Kompaniyets","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"11","key":"2024062715541743000_ciac724-B313","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical Status at 11 days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"2024062715541743000_ciac724-B314","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/jpids\/piaa115","article-title":"Multicenter interim guidance on use of antivirals for children with coronavirus disease 2019\/severe acute respiratory syndrome coronavirus 2","volume":"10","author":"Chiotos","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"9","key":"2024062715541743000_ciac724-B315","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2352-4642(20)30177-2","article-title":"COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study","volume":"4","author":"Gotzinger","year":"2020","journal-title":"Lancet Child Adolesc Health"},{"key":"2024062715541743000_ciac724-B316","author":"Ahmed"},{"issue":"16","key":"2024062715541743000_ciac724-B317","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with COVID-19","volume":"384","author":"REMAP-CAP Investigators","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"2024062715541743000_ciac724-B318","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe COVID-19 pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"2024062715541743000_ciac724-B319","doi-asserted-by":"publisher","first-page":"e948","DOI":"10.1097\/PCC.0000000000002511","article-title":"Clinical features of critical coronavirus disease 2019 in children","volume":"21","author":"Bhumbra","year":"2020","journal-title":"Pediatr Crit Care Med"},{"issue":"11","key":"2024062715541743000_ciac724-B320","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1001\/jama.2021.2091","article-title":"Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19","volume":"325","author":"Feldstein","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"2024062715541743000_ciac724-B321","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1186\/s13054-020-03332-4","article-title":"Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain","volume":"24","author":"Garcia-Salido","year":"2020","journal-title":"Crit Care"},{"key":"2024062715541743000_ciac724-B322","author":"US Food and Drug Administration"},{"issue":"2","key":"2024062715541743000_ciac724-B323","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/cpt.936","article-title":"Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients","volume":"104","author":"Kim","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2024062715541743000_ciac724-B324","author":"Eli Lilly and Company"},{"key":"2024062715541743000_ciac724-B325","author":"US Food and Drug Administration"},{"issue":"15","key":"2024062715541743000_ciac724-B326","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"2024062715541743000_ciac724-B327","author":"US Food and Drug Administration"},{"issue":"23","key":"2024062715541743000_ciac724-B328","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV antibody combination and outcomes in outpatients with COVID-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"2024062715541743000_ciac724-B329","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"key":"2024062715541743000_ciac724-B330","author":"Regeneron Pharmaceuticals"},{"key":"2024062715541743000_ciac724-B331","author":"Regeneron Pharmaceuticals"},{"key":"2024062715541743000_ciac724-B332","author":"Regeneron Pharmaceuticals"},{"key":"2024062715541743000_ciac724-B333","author":"Regeneron Pharmaceuticals"},{"key":"2024062715541743000_ciac724-B334","author":"Eli Lilly and Company; AbCellera Biologics Inc; Shanghai Junshi Bioscience Co, Ltd"},{"key":"2024062715541743000_ciac724-B335","author":"GlaxoSmithKline; Vir Biotechnology, Inc"},{"key":"2024062715541743000_ciac724-B336","author":"Vir Biotechnology, Inc; GlaxoSmithKline"},{"key":"2024062715541743000_ciac724-B337","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/jpids\/piab124","article-title":"Updated guidance on use and prioritization of monoclonal antibody therapy for treatment of COVID-19 in adolescents","volume":"11","author":"Wolf","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"5","key":"2024062715541743000_ciac724-B338","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1161\/CIRCULATIONAHA.120.048360","article-title":"Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic","volume":"142","author":"Belhadjer","year":"2020","journal-title":"Circulation"},{"issue":"3","key":"2024062715541743000_ciac724-B339","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/jpids\/piaa061","article-title":"COVID-19-associated pediatric multisystem inflammatory syndrome","volume":"9","author":"Leon MP","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"10237","key":"2024062715541743000_ciac724-B340","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(20)31094-1","article-title":"Hyperinflammatory shock in children during COVID-19 pandemic","volume":"395","author":"Riphagen","year":"2020","journal-title":"Lancet"},{"issue":"10239","key":"2024062715541743000_ciac724-B341","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(20)31103-X","article-title":"An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study","volume":"395","author":"Verdoni","year":"2020","journal-title":"Lancet"},{"key":"2024062715541743000_ciac724-B342","doi-asserted-by":"publisher","first-page":"E283","DOI":"10.1148\/radiol.2020202288","article-title":"Cardiac MRI of children with multisystem inflammatory syndrome (MIS-C) associated with COVID-19: case series","volume":"297","author":"Blondiaux","year":"2020","journal-title":"Radiology"},{"key":"2024062715541743000_ciac724-B343","doi-asserted-by":"publisher","first-page":"2492.e5","DOI":"10.1016\/j.ajem.2020.05.117","article-title":"Toxic shock-like syndrome and COVID-19: a case report of multisystem inflammatory syndrome in children (MIS-C)","volume":"38","author":"Greene","year":"2020","journal-title":"Am J Emerg Med"},{"issue":"8","key":"2024062715541743000_ciac724-B344","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/annrheumdis-2020-217960","article-title":"Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort","volume":"79","author":"Pouletty","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2024062715541743000_ciac724-B345","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/jpids\/piaa069","article-title":"Multisystem inflammatory syndrome in children during the coronavirus 2019 pandemic: a case series","volume":"9","author":"Chiotos","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"8","key":"2024062715541743000_ciac724-B346","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1097\/INF.0000000000002777","article-title":"Severe SARS-CoV-2 infection in children with suspected acute abdomen: a case series from a tertiary hospital in Spain","volume":"39","author":"Cabrero-Hernandez","year":"2020","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"2024062715541743000_ciac724-B347","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1056\/NEJMoa2021680","article-title":"Multisystem inflammatory syndrome in U.S. children and adolescents","volume":"383","author":"Feldstein","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"2024062715541743000_ciac724-B348","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa2021756","article-title":"Multisystem inflammatory syndrome in children in New York State","volume":"383","author":"Dufort","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"2024062715541743000_ciac724-B349","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/jama.2020.10369","article-title":"Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2","volume":"324","author":"Whittaker","year":"2020","journal-title":"JAMA"},{"issue":"32","key":"2024062715541743000_ciac724-B350","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.15585\/mmwr.mm6932e2","article-title":"COVID-19\u2013associated multisystem inflammatory syndrome in children\u2014United States, March\u2013July 2020","volume":"69","author":"Godfred-Cato","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"2024062715541743000_ciac724-B351","doi-asserted-by":"crossref","first-page":"e2116420","DOI":"10.1001\/jamanetworkopen.2021.16420","article-title":"Incidence of multisystem inflammatory syndrome in children among US persons infected with SARS-CoV-2","volume":"4","author":"Payne","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"11","key":"2024062715541743000_ciac724-B352","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.1097\/INF.0000000000003294","article-title":"Racial and ethnic disparities in multisystem inflammatory syndrome in children in the United States, march 2020 to February 2021","volume":"40","author":"Stierman","year":"2021","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"2024062715541743000_ciac724-B353","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/jamapediatrics.2021.0630","article-title":"Trends in geographic and temporal distribution of US children with multisystem inflammatory syndrome during the COVID-19 pandemic","volume":"175","author":"Belay","year":"2021","journal-title":"JAMA Pediatr"},{"issue":"2","key":"2024062715541743000_ciac724-B354","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2352-4642(20)30304-7","article-title":"A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national delphi process","volume":"5","author":"Harwood","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"issue":"9","key":"2024062715541743000_ciac724-B355","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/jama.2021.0694","article-title":"Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children","volume":"325","author":"Ouldali","year":"2021","journal-title":"JAMA"},{"key":"2024062715541743000_ciac724-B356","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jpeds.2020.06.045","article-title":"Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2 infection (MIS-C): a multi-institutional study from New York City","volume":"224","author":"Kaushik","year":"2020","journal-title":"J Pediatr"},{"key":"2024062715541743000_ciac724-B357","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jpeds.2020.06.044","article-title":"Characteristics, cardiac involvement, and outcomes of multisystem inflammatory syndrome of childhood associated with severe acute respiratory syndrome coronavirus 2 infection","volume":"224","author":"Capone","year":"2020","journal-title":"J Pediatr"},{"issue":"2","key":"2024062715541743000_ciac724-B358","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1097\/RHU.0000000000001734","article-title":"Role of biological agents in the treatment of SARS-CoV-2-associated multisystem inflammatory syndrome in children","volume":"28","author":"Celikel","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"2024062715541743000_ciac724-B359","author":"Centers for Disease Control and Prevention"},{"key":"2024062715541743000_ciac724-B360","author":"Centers for Disease Control and Prevention"},{"key":"2024062715541743000_ciac724-B361","author":"Royal College of Paediatrics and Child Health"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac724\/47465650\/ciac724.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/7\/e250\/58349175\/ciac724.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/7\/e250\/58349175\/ciac724.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T14:52:13Z","timestamp":1719499933000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/78\/7\/e250\/6692369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":361,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,9,5]]},"published-print":{"date-parts":[[2024,6,27]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac724","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,15]]},"published":{"date-parts":[[2022,9,5]]}}}